BIRC5 and cancer: Moreover, survivin has been identified as a target for cancer therapeutics [5,6], and several approaches to this direction have been explored, such as the implementation of inhibitors against survivin homodimerization or interaction with other proteins, inhibitors of survivin expression, and immunotherapy [6].